The CAR T-cell strategy vs bispecific antibodies Published 2019-03-26 Download video MP4 360p Recommendations 06:23 The benefits of bispecific antibodies over CAR-T cell therapy in lymphoma 1:08:32 Treating Lymphoma with Bispecific Antibodies | LRF Webinars 15:58 Understanding Intermittent Hormone Therapy For #ProstateCancer | #MarkScholzMD #AlexScholz #PCRI 04:51 BiTE®: Bispecific T Cell Engager 01:36 Immunology | Monoclonal Antibody Production 04:34 What Is the Future for CAR-T in Multiple Myeloma? 05:17 Antibody Dependent Cell Mediated Cytotoxicity (ADCC) | Effector cells in ADCC response 01:45 Using the available repertoire of bispecific antibodies for treating multiple myeloma 38:40 Bispecific antibodies in lymphoma: an update 01:36 Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma 40:15 CD19 Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus 03:00 Drawn to Science | T-cell bispecific antibodies 06:13 Lymphoma: Overview of Chimeric Antigen Receptor (CAR) T cells 04:45 Bispecifics Part 2: Monoclonal and Bispecific Antibodies 07:17 Immunology - Antibody Somatic (VDJ) Recombination I 02:40 The Mechanism of Action of CAR T 29:00 DLBCL in 2023: Top Docs Discuss the LATEST in Diffuse Large B-Cell Lymphoma | Treatments & Research 03:10 Immunology wars: Monoclonal antibodies 00:55 What are Bispecific Antibodies? Similar videos 04:01 What are the differences between CAR T-cell therapy and bispecific antibodies? 01:44 Bispecific antibodies vs CAR-T cells in DLBCL: the benefit of CAR-T therapy 04:35 Bispecific antibodies vs CAR T-cells for R/R multiple myeloma 12:15 CAR-T vs bispecific antibodies for lymphoma 02:52 Comparing the efficacy and curative potential of CAR-T therapy & bispecific antibodies in R/R DLBCL 01:25 Moving CAR T-cell therapy and bispecific antibodies in the consolidation setting 03:03 What are the key differences between bispecific antibodies and CAR T cells? 01:13 The future of CAR T-cells and bispecific antibodies to treat myeloma 01:23 Advantages of bispecific antibodies over CAR-T therapy in LBCL 02:52 Current immunotherapeutic approaches in DLBCL: the value of CAR-T cells and bispecific antibodies 04:53 CAR-T Cell Therapy vs. Bispecific Antibody Therapies in Relapsed Lymphoma 02:37 Efficacy of bispecific CD19/CD22 CAR T-cells in B-cell malignancies 04:10 The use of ADCs & bispecific antibodies before and after CAR-T therapy in third-line DLBCL 08:31 How to decide between bispecific antibodies or CAR T-cell therapies 04:27 The possibility of combining CAR-T therapy and bispecific antibodies in the treatment of NHL 02:45 Emerging treatments for myeloma: quadruplets, bispecific antibodies & CAR T-cells 19:37 Bispecific Monoclonal Antibodies and CAR T-Cell Therapy in Multiple Myeloma, Omar Nadeem, MD 08:14 Bispecific Versus CAR T-Cell Therapy for Myeloma and Bridging Therapy Needs for CAR-T 02:29 Emerging lymphoma therapies: bispecific antibodies and CAR T-cells 01:46 CAR-T therapy vs BiTEs in multiple myeloma: current outlooks & the importance of patient selection More results